ASX Share rice
Wed 05 Aug 2020 - 11:11:am (Sydney)

BOT Share Price

BOTANIX PHARMACEUTICALS LTDBOTPharmaceuticals, Biotechnology & Life Sciences

BOT Company Information

Name:

Botanix Pharmaceuticals Limited

Sector:

Healthcare

Industry:

Biotechnology

GIC Industry:

Biotechnology

GIC Sub Industry:

Biotechnology

Address:

50 Angove Street North Perth WA Australia 6006

Phone:

61 8 6555 2945

Full Time Employees:

11

MD, Pres & Exec. Chairman:

Mr. Vincent P. Ippolito

COO & Exec. Director:

Dr. Michael Thurn Ph.D.

Chief Scientific Officer & Exec. Director:

Dr. Henry William Bosch

Exec. Director:

Mr. Matthew Callahan

Company Sec.:

Mr. Simon Robertson C.A., B.Bus, M Appl. Fin, CA

Company Overview:

Botanix Pharmaceuticals Limited, a clinical stage cannabinoid therapeutics company, develops therapeutics for serious skin diseases in Australia. It offers BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers; BTX 1308, a transdermal gel formulation for the treatment of plaque psoriasis; BTX 1204, a transdermal gel formation for the treatment of atopic dermatitis; BTX 1701, a novel product for mild acne; and BTX 1801, a novel antimicrobial. The company is based in North Perth, Australia.

BOT Share Price Information

Shares Issued:

0.97B

Market Capitalisation:

$50.58M

Revenue (TTM):

$7.58M

Revenue Per Share (TTM):

$0.01

Earnings per Share:

$-0.022

Profit Margin:

-2.6201

Operating Margin (TTM):

$-2.62

Return On Assets (TTM):

$-0.50

Return On Equity (TTM):

$-0.88

Quarterly Revenue Growth (YOY):

0.619

Gross Profit(TTM):

$-11,944,351

Diluted Earnings Per Share (TTM):

$-0.024

BOT CashFlow Statement

CashFlow Date:

2019-06-30

Investments:

$-13,287

Change To Liabilities:

$3.12M

Total Cashflow From Investing Activities:

$-13,287

Net Income:

$-17,039,211

Total Cash From Operating Activities:

$-13,140,723

Depreciation:

$1.58K

Change To Account Receivables:

$-56,633

Sale Purchase Of Stock:

$-26,756

Capital Expenditures:

$13.29K

BOT Income Statement

Income Date:

2019-06-30

Income Before Tax:

$-17,039,211

Net Income:

$-17,039,211

Gross Profit:

$-11,944,351

Operating Income:

$-21,459,498

Other Operating Expenses:

$385.82K

Interest Expense:

$11.21K

Total Revenue:

$4.69M

Total Operating Expenses:

$21.46M

Cost Of Revenue:

$16.63M

BOT Balance Sheet

Balance Sheet Date:

2019-06-30

Total Liabilities:

$4.58M

Total Stockholder Equity:

$615.22K

Other Current Liabilities:

$100.15K

Total Assets:

$5.20M

Common Stock:

$33.89M

Retained Earnings:

$-34,532,499

Cash:

$4.70M

Total Current Liabilities:

$4.58M

Property - Plant & Equipment:

$12.21K

Net Tangible Assets:

$615.22K

Total Current Assets:

$5.19M

Net Receivables:

$483.27K

Short-Term Investments:

$12.21K

Accounts Payable:

$4.12M

Non Currrent Assets (Other):

$12.21K

Short-Term Investments:

$12.21

Non Current Liabilities Total:

$0

BOT Share Price History

BOT News

12 May, 2020
Taking the occasional loss comes part and parcel with investing on the stock market. And there's no doubt that Botanix...
13 Mar, 2020
Botanix Pharmaceuticals Limited's (ASX:BOT): Botanix Pharmaceuticals Limited, a clinical stage cannabinoid therapeutics...
13 Jan, 2020
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
14 Nov, 2019
Botanix Pharmaceuticals Limited (ASX:BOT) shareholders might be rather concerned because the share price has dropped...